Researchers developed a simple injection that may support the heart during the vulnerable weeks after a heart attack. The treatment is given into skeletal muscle and prompts the body to release ANP, a natural hormone that reduces stress on the heart.
A study of the work in Science showed that a single dose produced ANP for several weeks. The injection uses self-amplifying RNA (saRNA), a technology related to some modern vaccines, so muscle cells make extra ANP for a limited time and the hormone travels to the heart to help repair.
The researchers say the shot could reduce scarring, preserve healthy heart muscle, improve pumping function and lower long-term complications. Before human trials, the team will test safety, timing and dosing.
Difficult words
- vulnerable — easily harmed or needing protection
- skeletal muscle — muscle attached to bones used for movement
- hormone — chemical from the body that controls activity
- self-amplifying RNA — RNA that makes more copies inside cells
- scar — mark left on tissue after injury healsscarring
- preserve — keep something in its original or good condition
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How could a short-term injection that increases ANP change recovery after a heart attack for patients?
- What safety, timing, or dosing concerns should researchers check before they try this treatment in people?
- Would being treated by an injection into muscle feel more acceptable than a treatment given directly to the heart? Why or why not?
Related articles
New modular CAR-T system controls where and when cells attack
Researchers at the University of Chicago created GA1CAR, a modular CAR-T system that uses short-lived Fab fragments to guide and pause tumor targeting. In animal tests the same cells were redirected to different tumors and remained functional.
Gene Variant Raises Heart Failure Risk After Myocarditis in Children
A study found that a cardiomyopathy gene variant is more common in children who develop dilated cardiomyopathy after myocarditis. Researchers describe a "double hit" model and advise genetic testing to identify higher risk.